Modulating afferent signals to treat medical conditions

Abstract

This document provides methods and materials for modulating afferent nerve signals to treat medical conditions such as CHF, CHF respiration, dyspnea, peripheral vascular disease (e.g., peripheral arterial disease or venous insufficiency), hypertension (e.g., age-associated hypertension, resistant hypertension, or chronic refractory hypertension), COPD, sleep apnea, and chronic forms of lung disease where muscle dysfunction is a part of the disease pathophysiology. For example, methods and materials involved in using electrical and/or chemical techniques to block or reduce afferent nerve signals (e.g., nerve signals of group III and/or IV afferents coming from skeletal muscle and/or the kidneys) are provided.

What is claimed is: 
     
         1 . A method for increasing exercise tolerance of a mammal having heart failure, wherein said method comprises:
 (a) identifying a mammal having heart failure and reduced exercise tolerance, and   (b) applying a composition comprising clonidine to a muscle or kidney afferent nerve of said mammal under conditions wherein afferent nerve signals of said muscle or kidney afferent nerve are reduced or blocked.   
     
     
         2 . The method of  claim 1 , wherein said mammal is a human. 
     
     
         3 . The method of  claim 1 , wherein said method comprises applying said composition to a muscle afferent nerve. 
     
     
         4 . The method of  claim 1 , wherein said method comprises applying said composition to a kidney afferent nerve.